Navigation Links
Welsh shingles drug set for final hurdle
Date:3/23/2010

A new Welsh-developed drug to help alleviate the suffering of shingles could move a step closer for patients if the final stage of testing is given the go-ahead.

A new shingles drug (FV-100), discovered by Professor Chris McGuigan's team from Cardiff University's Welsh School of Pharmacy together with a virology group at the Rega Institute in Belgium and US biopharmaceutical company, Inhibitex Inc, is due to complete Phase II of its clinical trials.

If the drug completes Phase II it will enter the third and final stage which could see the drug being available to patients in less than three years.

Cardiff University's Professor of Medical Chemistry, Chris McGuigan, who led the team which discovered the new antiviral drug, said: "We are now entering the final and most crucial stage in the journey from the discovery of a new drug to the market.

"If we successfully complete this stage the drug would be available to help alleviate the pain and suffering for millions of shingles patients, not only in Wales but across the world."

Shingles is caused by the same viral infection that causes chicken pox. It is estimated that one-in-five people in the US, Europe and Japan will be affected by the condition during their lifetime.

The condition is characterised by skin lesions, blisters and rash, and acute pain, and in many cases, post-herpetic neuralgia which is a painful and often highly distressing condition resulting from nerve damage caused by the virus. Initial tests of FV-100 showed it has the potential to greatly reduce all of these symptoms.

In Phase I trials of FV-100, no serious adverse events in healthy volunteers were reported and data supported the potential for once-a-day dosing in future trials.Previous lab research has also shown the drug to be up to 10,000 times more potent against the virus than existing treatments.

Professor McGuigan added: "We believe this drug has the potential to be the most powerful inhibitor ever discovered to treat shingles.

"Each year only 15-20 new medicines are approved for clinical use and the chance of FV100 becoming an approved medicine improves the further we successfully progress through each of the clinical stages.

"We are incredibly excited at the prospect of FV-100 becoming commercially available in the future, and potentially being the first drug discovered in Cardiff University to make it to the marketplace."


'/>"/>

Contact: Chris Jones
JonesC83@cardiff.ac.uk
44-292-087-4731
Cardiff University
Source:Eurekalert

Related medicine news :

1. Welsh Tree LLC Proudly Presents the Release of the Celtic Pathways CD by Jason Evans, in Time for Saint Patrick's Day
2. Chicken Pox Shot Protects Against Shingles, Too
3. Chicken Pox Vaccine May Also Reduce Risk of Shingles Among Children
4. Food and Drug Administration Issues Final Rule Regarding Sale, Distribution, and Use of Cigarettes and Smokeless Tobacco
5. AKON Fragrance Finally Available at Akonfragrances.com
6. Morehead Associates, Inc. and Child Health Corporation of America (CHCA) Finalize Agreement for Employee and Physician Surveys and Consulting Services
7. Nine Healthcare Companies Named Finalists for Innovations in HealthcareSM ABBY Awards, to be Presented April 28th
8. 21 Healthcare Companies Achieve Semi-Finalist Status for Innovations in HealthcareSM ABBY Awards
9. Neovasc Completes Final Tranche of $1.537 Million Non-Brokered Private Placement
10. Patients with Lethal Lung Disease Finally Receive Recognition by Social Security Administration
11. Kiwanis Selects Three Finalists for Worldwide Service Project
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... ... TherapySites, the leading website and online marketing ... Association. This new relationship allows TherapySites to continue to extend their online ... and promotional offers. , "TCA is extremely excited about this new partnership, as ...
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer care, and ... in the eye of the beholder, according to experts who offered insights and commentary ... of Managed Care. For the full issue, click here . , For the ...
(Date:6/26/2016)... ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is helping ... fitness app. The fitness app plans to fix the two major problems leading the fitness ... size fits all type program , They don’t eliminate all the reasons people ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library ... City Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ... for fumigation is not a common occurrence, but a necessary one in the event that ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... June 24, 2016  Global Blood Therapeutics, Inc. (GBT) ... developing novel therapeutics for the treatment of grievous ... the closing of its previously announced underwritten public ... the public offering price of $18.75 per share. ... offered by GBT. GBT estimates net proceeds from ...
(Date:6/24/2016)... 24, 2016 ... the addition of the " Global Markets for ... This report focuses on ... updated review, including its applications in various applications. The ... which includes three main industries: pharmaceutical and biotechnology, food ...
(Date:6/24/2016)... -- The Academy of Managed Care Pharmacy (AMCP) today ... allow biopharmaceutical companies to more easily share health care ... coverage decisions, a move that addresses the growing need ... The recommendations address restrictions in the sharing of product ... a prohibition that hinders decision makers from accessing HCEI ...
Breaking Medicine Technology: